title: Safety and immunogenicity of chromatographically purified Vero cell rabies vaccine for intradermal pre- and post-exposure rabies prophylaxis.
abstract: Improved rabies pre- and post-exposure prophylaxis (PrEP and PEP) in developing countries uses an economic multi-site intradermal vaccination.
  
  
  OBJECTIVE
  To evaluate immunogenicity of chromatographically purified Vero cell vaccine (CPRV) for intradermal PrEP and PEP.
  
  
  METHODS
  The subjects received conventional PrEP with CPRV or PVRV in PrEP study or received intradermal PEP with CPRV or PVRV and rabies immunoglobulin in PEP study.
  
  
  RESULTS
  All subjects who received PrEP with CPRV had protective neutralizing antibody (Nab) titers (≥0.5 IU/ml) 14 days after completing vaccination. In PEP study, Nab titers in the CPRV groups reached ≥ 0.5 IU/ml in all subjects by day 14 through day 90 after vaccination. The geometric mean titers of Nab in the CPRV groups had significantly higher titers than the PVRV group on day 14 through day 365 (p < 0.05). No serious adverse reactions were observed.
  
  
  CONCLUSIONS
  CPRV is safe and immunogenic when given for intradermal PrEP and PEP.
authors.affiliation: Queen Saovabha Memorial Institute (WHO Collaborating Center for Research in Rabies), the Thai Red Cross Society, Rama 4Rd, Phatumwan, Bangkok 10330, Thailand.
authors.forename: Terapong
authors.initials: T
authors.lastname: Tantawichien
authors.forename: Suda
authors.initials: S
authors.lastname: Sibunruang
authors.forename: Thanphet
authors.initials: T
authors.lastname: Tantawichien
authors.forename: Jaruboot
authors.initials: J
authors.lastname: Angsanakul
authors.forename: Maneerat
authors.initials: M
authors.lastname: Benjavongkulchai
authors.forename: Kornvika
authors.initials: K
authors.lastname: Limsuwan
authors.forename: Piyada
authors.initials: P
authors.lastname: Udomchaisakul
authors.forename: Sumana
authors.initials: S
authors.lastname: Khomvilai
authors.forename: Visith
authors.initials: V
authors.lastname: Sitprija
mesh_terms: D000293:Adolescent; D000328:Adult; D000818:Animals; D057134:Antibodies, Neutralizing / Q000097:blood; D000914:Antibodies, Viral / Q000097:blood; D002522:Chlorocebus aethiops; D064420:Drug-Related Side Effects and Adverse Reactions / Q000453:epidemiology / Q000473:pathology; D005260:Female; D006801:Humans; D007271:Injections, Intradermal; D008297:Male; D008875:Middle Aged; D056990:Post-Exposure Prophylaxis / Q000379:methods*; D065129:Pre-Exposure Prophylaxis / Q000379:methods*; D011446:Prospective Studies; D011818:Rabies / Q000517:prevention & control*; D011819:Rabies Vaccines / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology* / Q000302:isolation & purification; D016896:Treatment Outcome; D014709:Vero Cells; D055815:Young Adult
chemical_list: D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D011819:Rabies Vaccines
keywords: intradermal injection; post-exposure prophylaxis; pre-exposure prophylaxis; rabies vaccine